Experience

• 

  Tech London Advocates & Global Tech Advocates

  • London, United Kingdom

  • Lead, Corporate/Start-up Partnerships (Corporate Innovation Working Group)

    • Sep 2018 - Present
    • London, United Kingdom

    • Wrote a 10,000-word whitepaper detailing the pattern behind successful corporate/start-up collaborations. • Developed a new, evidence-based model to improve the success of corporate innovation, digital transformation and and start-up collaborations initiatives, around 96% of which currently fail.• Organised, produced, marketed and secured sponsorship for an over-subscribed event on corporate/start-up collaborations, at London Technology Week, 2019.

• 

  Konica Minolta Business Solutions Europe GmbH

  • Germany
  • IT Services and IT Consulting
  • 700 & Above Employee

  • Programme Manager, Product Manager and Healthcare Lead (Business Innovation Centre, Europe)

    • Feb 2017 - Aug 2018

    • Led a collaboration with a start-up to reduce the time between breast cancer operations from three months to 100 seconds and follow-up operations by 50%. Delivered an enabling technology for the start-up, accelerating their ability to detect cancers reliably, accurately and safely, improve patient outcomes and lower healthcare costs. I incubated and product-managed this international, multidisciplinary partnership, which produced new patent applications for Konica Minolta, from idea up to clinical testing.• Catalysed, product-managed and incubated invention of an IoT-based tracking system to recover £30m a year in lost sales for an automotive retailer, and improve their customer experience and net promotor score. I led commercial and UX research, developed pricing and financial models, and managed international relationships to enable pilot testing.• Co-developed an IoT-based system to save Konica Minolta £5m a year from over-supplying stock to customers.• Co-led creation of an innovation engagement / technology transfer framework, to improve the selection and commercialisation process for new business incubations. I secured buy-in, resourcing and commitment from Konica Minolta Great Britain to spearhead the initiative.

  • Chief Analyst (Business Innovation Centre, Europe)

    • Feb 2017 - Apr 2017

    I conducted quantitative and qualitative research into applications of augmented and virtual reality to healthcare. Also recommended commercial and investment opportunities in molecular imaging, precision medicine and dynamic radiology.

  • Incubation Manager, Business and Healthcare Technologies (Business Innovation Centre, Europe)

    • Sep 2015 - Jan 2017

    • Co-led and product-managed development of an IoT-based asset tracking system to save Konica Minolta's UK operations £5m per year.• Alliance and product-managed a separate IoT-focussed collaboration, with a start-up, to improve Konica Minolta’s customer experience and net promoter score. • Alliance-managed the relationship with a medtech start-up, and delivered commercial and alternative financing research for strategic investments in the company.• Researched and recommended partnership opportunities with anti-counterfeiting, augmented reality and virtual reality companies, for cross-sector applications facilitating Konica Minolta’s digital transformation.

• 

  Silicon Real

  • Social Media and Digital Content Manager

    • Aug 2014 - Sep 2015

    Taking a lean, user-centric approach, I grew this start-up's social media following by 400% over eight months, to 12,000, by engaging key influencers and optimising audience-focussed content. In addition, I increased online views by 300% per week, by generating audience-focused, informative, bite-sized content, with ‘click-bait’ titles.

  • Business Development Manager

    • May 2014 - Jul 2014

    I researched and generated interview and commercial sponsorship leads.

• 

  IQPC

  • London, United Kingdom

  • Senior Conference Producer

    • Mar 2013 - Dec 2013
    • London, United Kingdom

    Developed a portfolio of expert-led biopharmaceutical R&D and manufacturing conferences and workshops, held in the UK and Germany. I commissioned additional white papers, reviews, podcasts and infographics in collaboration with Pharma IQ, IQPC's online biopharmaceutical portal.I converted commercial and technical analysis into enabling strategies for drug discovery, development, toxicity testing, disease modelling and risk mitigation. I delivered evidence-based critiques, problem-solving case studies and discussion forums for CXOs, VPs, Directors and Heads across therapeutic areas. This required presenting new and unpublished research across basic, pre-clinical, translational and clinical research, manufacturing and production, from blue-chip companies, international regulators and Ivy League universities. Projects included: Epigenetic Innovations, Clinically-Relevant Drug Transporters, Predictive Toxicology, Cell-Based Assays, Pathogen Safety [biopharmaceutical manufacturing]. Key achievements:• Facilitated guidance from regulatory, industry and academic experts to improve clients’ product development. • Synthesised research allowing clients to mitigate risk, leverage big data and increase translational efficacy. • Recommended on LinkedIn by NASA and Oxford University scientists for the quality of information I engendered.

• 

  SMi Group

  • Senior Conference Producer

    • Sep 2011 - Jan 2013

    Grew and launched a series of biopharmaceutical, utility and conventional energy conferences, workshops and masterclasses. This involved interpreting, contextualising and monetising new and unpublished research across three independent areas of science and technology. Biopharmaceuticals: I worked on topics incorporating nanobiotechnology, stratified/personalised medicine and big data (before the term 'big data' was being applied to biological problems). Projects included: Next-Generation Sequencing, Orphan Drugs and Rare Diseases, Biomarkers, Controlled-Release [drug formulations], Quality by Design, and Diabetes, Cardiovascular and Renal Complications.Energy: I addressed commercial markets, enabling technologies, data analytics and cybersecurity for oil and gas operations. Projects included: Liquefied Natural Gas, Oil and Gas Telecommunications, and Exploration & Production Information and Data Management.Utilities: I addressed international policy, investment incentives and technology drivers for renewable energy, water management and waste-to-energy developments. Projects included: Grid-Scale Energy Storage, Smart Water Systems and Energy from Waste.Key achievements:• Launched six new conferences, which all became repeat events, in markets SMi had no exposure in or data for. One, in utilities, grossed sponsorship revenue 400% higher than the company's sector average. • Redefined the focus of three existing conferences and increased their yearly revenues by up to 200%.• Secured sponsorship from two top-15 pharmaceutical companies for the first time in the company’s history.• Made over 1,000 senior-level contacts across Fortune 500 companies, corporate law, finance, Ivy League universities and international polity, including the British, Danish and Scottish parliaments, European Commission and Welsh Assembly.

• 

  Visiongain

  • United Kingdom
  • Market Research
  • 1 - 100 Employee

  • Senior Conference Producer

    • Nov 2010 - Aug 2011

    Consolidated the revenue streams of existing meetings, and topic-generated and launched new conferences and workshops for the pharmaceutical division. Including projects since 2008, I managed global relationships with a total of 500 clients and built and monetised a database of 4,000 experts across key markets.Projects included: GPCR & Kinase Targets, Cell-Based Assays, Pre-filled Syringes, Pricing and Reimbursement for Medical Devices, Lyophilisation Americas, Recombinant Antibodies, Clinical Trial Logistics & Supply.Key achievements:• Launched my tenth inaugural conference, which immediately became one of the top-two revenue-generating meetings in the company’s portfolio.• Redefined the commercial focus of five existing meetings and increased their yearly revenues, during the Great recession, by 10 – 100%.• Secured sponsorship for the company from two top-10 pharmaceutical companies for the first time.

  • Conference Producer

    • Aug 2008 - Oct 2010

    Grew and launched a portfolio of pharmaceutical and biotechnology conferences and workshops in the UK and USA. I provided market analysis, scientific strategy and problem-solving case studies for CXOs, VPs, Directors and Heads across therapeutic areas. This involved interpreting and contextualising new and unpublished scientific research across basic, pre-clinical, translational and clinical development, manufacturing, production and post-marketing surveillance. I conducted in-depth research into drug discovery and development for small-molecule, biologic and advanced therapy medicinal products. Examples include: applying genomics and proteomics to vaccine design and engineering; manufacturing the first medicine using synthetic biology; targets for cognition-enhancing drugs. I also worked with one of the inventors of the cervical cancer vaccine. Projects included: CNS Drug Development, Recombinant Antibodies, Monoclonal Antibodies, Vaccine R&D, the Japanese Pharmaceutical Market, Diabetes & Diabetic Retinopathy, Vaccine Manufacturing, Glaucoma & Retinopathies, Pain Management, Translational Regenerative Medicine, Pricing and Reimbursement for Medical Devices, GPCR & Kinase Targets, Cell-Based Assays, Contract Manufacturing, Lyophilisation.Key achievements:• Launched nine new conferences during 2008 – 2010, each earning up to 10 times more than established meetings.• Redefined the focus of four existing meetings and increased their yearly revenues by 50 – 500%.• Managed global relationships with 400 clients and monetised a database of 3,000 experts, including regulators and venture capitalists, across developed and emerging markets.• Initiated contact with, and negotiated contracts for, five new media partners to publicise the division's conferences.• Led an information-sharing initiative with visiongain's reports division, improving the calibre of our publications.